At Bharat Parenterals Limited, our CDMO vertical offers
full-spectrum contract development and manufacturing services
designed to meet the evolving needs of pharmaceutical
companies operating in emerging markets. We
provide cost-effective, high-quality development, scale-up,
and manufacturing solutions tailored for diverse regulatory
and market environments.
Emerging Market Expertise
We understand local registration requirements,
procurement systems, and quality expectations across
semi-regulated markets.
Integrated CDMO Model
Development to delivery under one roof, minimizing time
and cost while ensuring quality.
Agile & Cost-Effective
Lean manufacturing and optimized processes ideal for
volume-driven, price-sensitive markets.
Customizable Engagement
Private label, co-development, tech transfer, or
exclusive licensing — flexible models for every
business.
Quality You Can Trust
Strict adherence to cGMP and international compliance
standards.
Bharat Parenterals’ India Branded formulation business, led by Varenyam Healthcare Pvt. Ltd., focuses on innovative solutions for the Indian market. From government tenders to branded generics, Varenyam's core philosophy — “Innovexa: Innovation with Excellence” — has driven the success of market-first products like Sugammadex injection and atracurium besylate, making it one of India’s top 5 anesthesia companies.
learn more
learn more
Ethical Marketing Approach
Focused on high-quality generics and ethical drug marketing
First-to-Market Innovations
Pioneered Sugammadex and drug-specific time-temperature indicators for cold chain optimisation
Top 5 Anesthesia Company
Rapidly scaled within 5 years with 180+ sales professionals
Therapeutic Leadership
Expertise in anesthesia and neuromuscular blockers while diversifying to other niche therapies in near future
Strategic Expansion
From government tenders to leading branded generic market share
Innoxel Lifesciences, part of the Bharat Parenterals Limited Group, specializes in developing complex generics for highly regulated markets, including the USA and EU. With a strong focus on sterile injectables and oral liquids, Innoxel has successfully developed 20+ in-house products and is poised for success in liposome-based injectables and long-acting formulations. Their robust R&D capabilities and ongoing regulatory compliance ensure a smooth market entry.
learn more
learn more
Regulatory Excellence
Successfully cleared USFDA inspections and preparing for EU-GMP audits
Innovative Drug Development
Specializes in liposome-based injectables and long-acting formulations
Strong R&D Capabilities
Backed by 70 scientists driving innovation in complex products
Diverse Product Portfolio
20+ in-house developed products for US and EU markets
Oncology and General Product Expertise
Dedicated blocks for specialty drug production
Scalability and Compliance
Full compliance with stringent global regulations